Biotech wind-down: licensing quality and lab records beside the IP sale

What happens to records when a biotech winds down

When a biotech winds down, a small retained team markets the programs and IP, settles obligations and returns what is left to shareholders or creditors. Each program's data package travels with the IP to its buyer. The rest of the company's records, from SOPs and deviation files to lab-notebook metadata and instrument logs, are often archived in a hurry or lost when software subscriptions lapse.

Those operating records can be licensed for AI training beside the IP sale, with the approval of whoever controls the wind-down. Patient-level clinical data is a different matter: it stays out unless the consent terms permit the use and the data has been de-identified.

Why the wind-down window matters

The window is short. The eQMS, the electronic lab notebook and LIMS are usually subscription systems, and the people who administer them are often released in the first workforce reduction. Once a vendor contract ends without a complete export, the deviation history, CAPA files and notebook audit trails can be impossible to rebuild.

Many biotechs also have record-retention obligations that outlast operations, so counsel will set a retention plan in any case. A licensing review fits inside that work: the exports that satisfy retention can be inventoried for licensing at the same time, if the people who control the company agree.

AI developers value this material because it records scientific and quality work with outcomes: an out-of-specification result, the investigation that followed, the root cause, the CAPA and whether it worked. Records like that sit almost entirely inside companies.

Operating records vs clinical data

For health information covered by HIPAA, HHS guidance describes two de-identification methods: Expert Determination, where a qualified expert documents that re-identification risk is very small, and Safe Harbor, which removes 18 specified identifiers (HHS de-identification guidance). Whether a sponsor's trial data is covered by HIPAA at all is a question for counsel, and informed consent forms may restrict secondary use either way.

Scrutiny of sensitive data in distressed sales is real. In 23andMe's 2025 bankruptcy, the consumer privacy ombudsman appointed in the case recommended that any transfer of customers' genetic or personally identifiable data be barred without renewed opt-in consent (The Record). That is why this playbook keeps patient-level data out of scope and concentrates on operating records.

This is general information, not legal, tax or financial advice. Confirm with your own counsel before acting.

Who controls the decision

• Board-led dissolution: the board and the officers running the wind-down decide on any license, usually alongside the IP sales and the plan for distributing cash.
• Assignment for the benefit of creditors: the company transfers its assets to an assignee who holds them in trust, liquidates them and distributes the proceeds to creditors (overview of assignments for the benefit of creditors); the assignee decides, and procedures vary by state.
• Court-supervised cases: asset sales run under court supervision, and estate counsel advises on which approvals a records license would need.

A partner should never approach a company in wind-down around the people who control it. Restructuring professionals who already serve as wind-down officer, chief restructuring officer or assignee are best placed to raise the idea; the wind-down advisor partner page explains how that partner role works.

The wind-down timeline with a records step

Illustrative timeline; the board's or the liquidator's plan sets the real dates.

Who to talk to

• The CEO or CFO running the wind-down, or the appointed wind-down officer.
• The head of quality, who knows what the eQMS holds and how far back it goes.
• The IT lead and the ELN and LIMS administrators, who can run complete exports.
• Company counsel, who owns the retention plan and reviews consent forms and collaboration agreements.
• The banker running the IP sale, so a records license never cuts across a program's data package.
• The board, assignee or trustee whose approval is required.

What to say to the wind-down lead

What to preserve before systems go dark

• Full eQMS export: controlled documents with revision history, deviations, CAPAs, change controls, audits and training
• ELN export including metadata, templates, protocols and audit trails, not only PDF printouts
• LIMS sample and run histories and instrument logs
• Shared drives and document management with folder structure intact
• Email and chat archives kept under the retention plan
• A written map of which program data packages went to which IP buyer
• A list of consent forms, collaboration agreements and CRO contracts that restrict any record set

The introduction checklist for quality inspection records helps structure the inventory. Medical device companies with similar quality systems are covered in the guide for QMSR and ISO 13485 consultants, and the guide to closing an engineering firm shows the same retention-first approach in another industry.

When not to bother

• The company never reached 50+ full-time employees at peak (contractors excluded). Many early-stage biotechs are smaller, and contract research staff do not count.
• The records are mostly patient-level clinical data.
• The IP buyers are taking all records, including quality and lab history.
• Validated systems were shut down without exports.
• Nobody with authority to approve a license is engaged.

How the introduction and reward work

The partner introduces the company, with the controlling party's agreement, through a referral link or the referral form. SourceX then qualifies the company on size, history, data breadth and rights; the retained team completes a data inventory; price and terms are agreed; AI labs and data buyers review; and the license closes with delivery and payment to the company or estate.

Partners earn 25% of the eligible platform fees SourceX actually collects from the referred company's licensing deals, capped at $100,000 per referred company. The reward is payable only after the buyer pays and SourceX receives its fee; no reward is guaranteed, and it never reduces what the company receives. If you hold a fiduciary role in the wind-down, discuss any referral reward with counsel before registering, since it may need disclosure or approval.

Next step

Ask the wind-down lead for the termination dates of the eQMS, ELN and LIMS contracts, then run the company fit checker against the who qualifies baseline. If the company fits and the controlling party agrees, register as a partner and make the introduction.